Home Newsfeeds Autonomous Research Initiates Coverage On Ryan Specialty Holdings with Underperform Rating, Announces Price Target of $35

Autonomous Research Initiates Coverage On Ryan Specialty Holdings with Underperform Rating, Announces Price Target of $35

Autonomous Research initiates coverage on Ryan Specialty Holdings (NYSE:RYAN) with a Underperform rating and announces Price Target of $35.

byBenzinga Newsdesk

February 21, 2023

1 minute read

Autonomous Research initiates coverage on Ryan Specialty Holdings (NYSE:RYAN) with a Underperform rating and announces Price Target of $35.

Analyst Ratings

Expert Outlook: Fusion Pharmaceuticals Through The Eyes Of 6 Analysts

By Benzinga Insights

January 26, 10:00 AM

6 analysts have shared their evaluations of Fusion Pharmaceuticals (NASDAQ:FUSN) during the recent three months, expressing a mix…

FUSN

Trulieve Significantly Narrows Q3 Loss Thanks To Lower Operating Expenses

By Nina Zdinjak

November 9, 9:55 AM

Florida-based cannabis company Trulieve Cannabis Corp. (CSE: TRUL) (OTCQX: TCNNF) reported its financial results Thursday for the third quarter, disclosing revenue of $275.2 million compared to $295.4 million in the same period a year ago and $282 million in th

CSE:TRUL

Analyst Ratings

The Latest Analyst Ratings for Taysha Gene Therapies

By Benzinga Insights

September 20, 12:00 PM

Within the last quarter, Taysha Gene Therapies (NASDAQ:TSHA) has observed the following analyst ratings: Bullish Somewhat Bullish Indifferent…

TSHA

‘Prepare For Crash,’ Warns ‘Rich Dad, Poor Dad’ Author Robert Kiyosaki After Eye-Opening Restaurant Encounter

By Bhavik Nair

June 25, 9:00 PM

“Rich Dad, Poor Dad” author Robert Kiyosaki explained in a tweet why he thinks a crash might be inevitable, citing his visit to a restaurant during the weekend and highlighting the low prices and empty tab

BTC

Autonomous Research Initiates Coverage On Ryan Specialty Holdings with Underperform Rating, Announces Price Target of $35

Related Posts

Expert Outlook: Fusion Pharmaceuticals Through The Eyes Of 6 Analysts

Trulieve Significantly Narrows Q3 Loss Thanks To Lower Operating Expenses

The Latest Analyst Ratings for Taysha Gene Therapies

‘Prepare For Crash,’ Warns ‘Rich Dad, Poor Dad’ Author Robert Kiyosaki After Eye-Opening Restaurant Encounter